This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameArotinolol
Accession NumberDB09204
TypeSmall Molecule
GroupsApproved
Description

Arotinolol is a medication in the class of mixed alpha/beta blockers.

Structure
Thumb
SynonymsNot Available
External IDs S-596
Product Ingredients Not Available
ProductsNot Available
International Brands
NameCompany
AlmarlNot Available
Brand mixturesNot Available
Categories
UNII394E3P3B99
CAS number68377-92-4
WeightAverage: 371.53
Monoisotopic: 371.07959045
Chemical FormulaC15H21N3O2S3
InChI KeyBHIAIPWSVYSKJS-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
IUPAC Name
5-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}-1,3-thiazol-4-yl)thiophene-2-carboxamide
SMILES
CC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=O
Pharmacology
Indication

Used in the treatment of high blood pressure.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arotinolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Arotinolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Arotinolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideArotinolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acetylcholine.Approved
AcetyldigitoxinArotinolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Arotinolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arotinolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Arotinolol.Approved, Illicit
AlfuzosinArotinolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Arotinolol.Approved, Investigational
AmbenoniumAmbenonium may increase the bradycardic activities of Arotinolol.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Arotinolol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Arotinolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Arotinolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Arotinolol.Approved
AmobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Arotinolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arotinolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Arotinolol.Approved
AndrographolideHMPL-004 may decrease the antihypertensive activities of Arotinolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Arotinolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Arotinolol.Approved
ApocyninAcetovanillone may decrease the antihypertensive activities of Arotinolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Arotinolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Arotinolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Arotinolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Arotinolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Arotinolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Arotinolol.Experimental
BarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Arotinolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Arotinolol.Approved
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arotinolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Arotinolol.Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arotinolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Arotinolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Arotinolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Arotinolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Arotinolol.Investigational
BucindololArotinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arotinolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Arotinolol.Approved, Investigational
CabergolineArotinolol may increase the vasoconstricting activities of Cabergoline.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Arotinolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Arotinolol.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Arotinolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbetocin.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Arotinolol.Approved
CarvedilolArotinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Arotinolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Arotinolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arotinolol.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
ChlorpropamideArotinolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Arotinolol.Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the antihypertensive activities of Arotinolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Arotinolol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Arotinolol.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Arotinolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Conivaptan.Approved, Investigational
CurcuminCurcumin may decrease the antihypertensive activities of Arotinolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Arotinolol.Approved
DapoxetineThe serum concentration of Arotinolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Arotinolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Arotinolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Desflurane.Approved
DeslanosideArotinolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Arotinolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Arotinolol.Approved
DigitoxinArotinolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinArotinolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Arotinolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Arotinolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Arotinolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Arotinolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Arotinolol.Approved
DoxazosinArotinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Arotinolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Arotinolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
DuloxetineArotinolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Arotinolol.Investigational
E-6201E6201 may decrease the antihypertensive activities of Arotinolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Arotinolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Arotinolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Arotinolol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Arotinolol.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Arotinolol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Arotinolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Arotinolol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Arotinolol.Approved
Ergoloid mesylateArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineArotinolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Arotinolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arotinolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Arotinolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
EtoperidoneThe serum concentration of Arotinolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Arotinolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Arotinolol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Arotinolol.Approved
FentanylFentanyl may increase the bradycardic activities of Arotinolol.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fimasartan.Approved
FingolimodArotinolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Arotinolol.Approved, Withdrawn
FluoxetineThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Arotinolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Arotinolol.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Arotinolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Arotinolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Arotinolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Arotinolol.Approved, Nutraceutical
GlibornurideArotinolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideArotinolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideArotinolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideArotinolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneArotinolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideArotinolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideArotinolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Arotinolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Halothane.Approved, Vet Approved
HexobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Arotinolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Arotinolol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Arotinolol.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Arotinolol.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Arotinolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Arotinolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Arotinolol.Approved
IloprostThe risk or severity of adverse effects can be increased when Arotinolol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imipramine.Approved
IndalpineThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Arotinolol.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
IndoraminArotinolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkArotinolol may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Arotinolol.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Arotinolol.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Arotinolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Arotinolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Arotinolol.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Arotinolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Arotinolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Arotinolol.Approved
LabetalolArotinolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lacidipine.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Arotinolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levobupivacaine.Approved
LevodopaArotinolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Arotinolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Arotinolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Arotinolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Arotinolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Arotinolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.Approved
MalathionMalathion may increase the bradycardic activities of Arotinolol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Arotinolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Arotinolol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Arotinolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Arotinolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Arotinolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Arotinolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Arotinolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Arotinolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Arotinolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Arotinolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Arotinolol.Approved
MethohexitalThe serum concentration of Arotinolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Arotinolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Arotinolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Arotinolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Arotinolol.Investigational
MethylphenobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arotinolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Arotinolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Arotinolol.Approved, Investigational
MidodrineArotinolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Arotinolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Arotinolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Arotinolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Arotinolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Arotinolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Arotinolol.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Arotinolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Arotinolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Arotinolol.Approved, Investigational
NefazodoneThe serum concentration of Arotinolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Arotinolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Arotinolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Arotinolol.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Arotinolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Arotinolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Arotinolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Arotinolol.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Arotinolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Arotinolol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Arotinolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arotinolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Arotinolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Arotinolol is combined with Obinutuzumab.Approved
OleandrinArotinolol may increase the bradycardic activities of Anvirzel.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Arotinolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Arotinolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Arotinolol.Approved
OuabainArotinolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Arotinolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Arotinolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Arotinolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Arotinolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Arotinolol.Approved
ParoxetineThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Arotinolol.Approved, Investigational
PentobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Arotinolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Arotinolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Arotinolol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Arotinolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Arotinolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Arotinolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pramipexole.Approved, Investigational
PrazosinArotinolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Arotinolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Arotinolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Arotinolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Arotinolol.Approved
PropafenoneThe serum concentration of Arotinolol can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Arotinolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Arotinolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Arotinolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Arotinolol.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Arotinolol.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Arotinolol.Approved
RasagilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Arotinolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Arotinolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Arotinolol.Experimental, Investigational
RifampicinThe serum concentration of Arotinolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Arotinolol can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Arotinolol.Approved
RisperidoneArotinolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Arotinolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Arotinolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sacubitril.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Arotinolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Arotinolol.Approved
SecobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Arotinolol.Approved
SertralineThe serum concentration of Arotinolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sevoflurane.Approved, Vet Approved
SilodosinArotinolol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Arotinolol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Arotinolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Arotinolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Arotinolol is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Arotinolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Arotinolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Arotinolol.Withdrawn
TamsulosinArotinolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Arotinolol.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Arotinolol.Approved
TerazosinArotinolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Arotinolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Arotinolol.Withdrawn
ThiopentalThe serum concentration of Arotinolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Arotinolol.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Arotinolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Arotinolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
TolazamideArotinolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolazoline.Approved, Vet Approved
TolbutamideArotinolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Arotinolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Arotinolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Arotinolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Arotinolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Arotinolol.Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Arotinolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
TrimazosinArotinolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TubocurarineTubocurarine may increase the bradycardic activities of Arotinolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Arotinolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Arotinolol.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Arotinolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Arotinolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Arotinolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Arotinolol.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Zhao J, Golozoubova V, Cannon B, Nedergaard J: Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes. Can J Physiol Pharmacol. 2001 Jul;79(7):585-93. [PubMed:11478592 ]
  2. Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D: A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord. 2003 Aug;9(6):341-7. [PubMed:12853233 ]
  3. Wu H, Zhang Y, Huang J, Zhang Y, Liu G, Sun N, Yu Z, Zhou Y: Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. Hypertens Res. 2001 Sep;24(5):605-10. [PubMed:11675958 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentHypertension,Essential1
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0225 mg/mLALOGPS
logP2.38ALOGPS
logP2.54ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)9.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.24 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity96.71 m3·mol-1ChemAxon
Polarizability40.37 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thiophene carboxamides. These are compounds containing a thiophene ring which bears a carboxamide.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiophenes
Sub ClassThiophene carboxylic acids and derivatives
Direct ParentThiophene carboxamides
Alternative ParentsAlkylarylthioethers / 2,5-disubstituted thiophenes / 2,4-disubstituted thiazoles / Heteroaromatic compounds / Secondary alcohols / Primary carboxylic acid amides / 1,2-aminoalcohols / Sulfenyl compounds / Dialkylamines / Azacyclic compounds
SubstituentsAryl thioether / Thiophene carboxamide / 2,4-disubstituted 1,3-thiazole / 2,5-disubstituted thiophene / Alkylarylthioether / Azole / Thiazole / Heteroaromatic compound / 1,2-aminoalcohol / Carboxamide group
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Drug created on October 19, 2015 13:52 / Updated on August 02, 2017 17:33